These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 7801735)

  • 1. Follow-up study of MS patients treated with high-dose intravenous methylprednisolone.
    Frequin ST; Lamers KJ; Barkhof F; Borm GF; Hommes OR
    Acta Neurol Scand; 1994 Aug; 90(2):105-10. PubMed ID: 7801735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.
    Zivadinov R; Rudick RA; De Masi R; Nasuelli D; Ukmar M; Pozzi-Mucelli RS; Grop A; Cazzato G; Zorzon M
    Neurology; 2001 Oct; 57(7):1239-47. PubMed ID: 11591843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS.
    Visser LH; Beekman R; Tijssen CC; Uitdehaag BM; Lee ML; Movig KL; Lenderink AW
    Mult Scler; 2004 Feb; 10(1):89-91. PubMed ID: 14760960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re-examining the effects of high-dose intravenous methylprednisolone for secondary progressive multiple sclerosis.
    Jalipa FGU; Espiritu AI; Pasco PMD
    Neurodegener Dis Manag; 2021 Apr; 11(2):177-185. PubMed ID: 33703936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CSF myelin basic protein, IgG and IgM levels in 101 MS patients before and after treatment with high-dose intravenous methylprednisolone.
    Frequin ST; Barkhof F; Lamers KJ; Hommes OR; Borm GF
    Acta Neurol Scand; 1992 Sep; 86(3):291-7. PubMed ID: 1384263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A transcranial magnetic stimulation study evaluating methylprednisolone treatment in multiple sclerosis.
    Fierro B; Salemi G; Brighina F; Buffa D; Conte S; La Bua V; Piazza A; Savettieri G
    Acta Neurol Scand; 2002 Mar; 105(3):152-7. PubMed ID: 11886356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica.
    Yamasaki R; Matsushita T; Fukazawa T; Yokoyama K; Fujihara K; Ogino M; Yokota T; Miyamoto K; Niino M; Nomura K; Tomioka R; Tanaka M; Kawachi I; Ohashi T; Kaida K; Matsui M; Nakatsuji Y; Ochi H; Fukaura H; Kanda T; Nagaishi A; Togo K; Mizusawa H; Murai H; Kira J
    Mult Scler; 2016 Sep; 22(10):1337-48. PubMed ID: 26564994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of intravenous methylprednisolone on the number, size and confluence of plaques in relapsing-remitting multiple sclerosis.
    Zivadinov R; Zorzon M; De Masi R; Nasuelli D; Cazzato G
    J Neurol Sci; 2008 Apr; 267(1-2):28-35. PubMed ID: 17945260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral prednisone taper following intravenous steroids fails to improve disability or recovery from relapses in multiple sclerosis.
    Perumal JS; Caon C; Hreha S; Zabad R; Tselis A; Lisak R; Khan O
    Eur J Neurol; 2008 Jul; 15(7):677-80. PubMed ID: 18459972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS.
    Ramo-Tello C; Grau-López L; Tintoré M; Rovira A; Ramió i Torrenta L; Brieva L; Cano A; Carmona O; Saiz A; Torres F; Giner P; Nos C; Massuet A; Montalbán X; Martínez-Cáceres E; Costa J
    Mult Scler; 2014 May; 20(6):717-25. PubMed ID: 24144876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-cell subsets in the cerebrospinal fluid and peripheral blood of multiple sclerosis patients treated with high-dose intravenous methylprednisolone.
    Frequin ST; Lamers KJ; Borm GF; Barkhof F; Jongen PJ; Hommes OR
    Acta Neurol Scand; 1993 Aug; 88(2):80-6. PubMed ID: 8213063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical impact of intravenous methylprednisolone in attacks of multiple sclerosis.
    Nos C; Sastre-Garriga J; Borràs C; Río J; Tintoré M; Montalban X
    Mult Scler; 2004 Aug; 10(4):413-6. PubMed ID: 15327039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose methylprednisolone infusions in relapsing and in chronic progressive multiple sclerosis patients. One year follow-up.
    Bergamaschi R; Versino M; Raiola E; Citterio A; Cosi V
    Acta Neurol (Napoli); 1993 Feb; 15(1):33-43. PubMed ID: 8456594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of rebound effect after natalizumab withdrawal in multiple sclerosis. Study of two high-dose methylprednisolone schedules.
    Fuentes-Rumí L; Hernández-Clares R; Carreón-Guarnizo E; Valero-López G; Iniesta-Martinez F; Cabrera-Maqueda JM; León-Hernández A; Zamarro-Parra J; Morales-Ortiz A; Meca-Lallana JE
    Mult Scler Relat Disord; 2020 Sep; 44():102311. PubMed ID: 32593958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of the long term effect of mitoxantrone on neurological disability in patients with active multiple sclerosis].
    Mesaros S; Stojsavljević N; Dujmović I; Mandić E; Drulović J
    Srp Arh Celok Lek; 2004; 132(7-8):209-13. PubMed ID: 15615176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications.
    Fox RJ; Fisher E; Tkach J; Lee JC; Cohen JA; Rudick RA
    Mult Scler; 2005 Apr; 11(2):140-5. PubMed ID: 15794385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group.
    Beck RW; Cleary PA; Trobe JD; Kaufman DI; Kupersmith MJ; Paty DW; Brown CH
    N Engl J Med; 1993 Dec; 329(24):1764-9. PubMed ID: 8232485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Responsiveness of walking-based outcome measures after multiple sclerosis relapses following steroid pulses.
    Filipović Grčić P; Matijaca M; Lušić I; Čapkun V
    Med Sci Monit; 2011 Dec; 17(12):CR704-10. PubMed ID: 22129902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes of the MS functional composite and EDSS during and after treatment of relapses with methylprednisolone in patients with multiple sclerosis.
    Patzold T; Schwengelbeck M; Ossege LM; Malin JP; Sindern E
    Acta Neurol Scand; 2002 Mar; 105(3):164-8. PubMed ID: 11886358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.